Pancreate

Pancreate (proisletide acetate) is a first-in-class bioactive peptide developed by CureDM, previously in collaboration with Sanofi. It is a synthetic version of a naturally occurring human peptide sequence known as HIP-2B (Human Islet Peptide 2B), which is derived from the Regenerating (REG) protein family. Pancreate is designed to stimulate the differentiation of pancreatic progenitor cells into functional, insulin-producing neo-islets. This regenerative approach aims to restore endogenous insulin production and glucose homeostasis in patients with type 1 and type 2 diabetes, potentially offering a disease-modifying alternative to exogenous insulin therapy. Although the drug reached early clinical trials, development was largely discontinued after Sanofi terminated its licensing agreement with CureDM in 2014.

Brand names

Pancreate

Other names

proisletide acetateproisletideHuman Islet Peptide 2B